On September 21, 2022 Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, reported a strategic collaboration with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;NASDAQ: EVO) (Press release, Evotec, SEP 21, 2022, prnewswire.com/news-releases/adapsyn-bioscience-enters-into-strategic-collaboration-with-evotec-301628703.html [SID1234621330]). Under the collaboration, Evotec will have the opportunity to evaluate small molecules developed by Adapsyn as potential therapeutic candidates in proprietary and partnered drug discovery projects.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Adapsyn platform uses artificial intelligence and machine learning to identify and isolate novel drug-like metabolites from microbes for downstream assay and development. Evotec has extensive biochemical, cellular, and phenotypic screening capabilities, and particular expertise in natural product drug discovery and development. The multi-year collaboration will provide Evotec with libraries of bioactive small molecules to screen against high value targets of interest to Evotec and its partners. Adapsyn will be responsible for library generation and compound production efforts.
Evotec gains access to novel drug-like small molecules from microorganisms for its hit identification capabilities
Financial details were not disclosed.
Dr Dirk Ullmann, Global Head of Drug Discovery Services at Evotec, said: "Combining Adapsyn’s libraries of drug-like molecules from microorganisms with Evotec’s extensive hit identification capabilities provides an exciting opportunity to broaden the scope of natural products as a source for drug discovery. We look forward to working closely with the highly specialised team at Adapsyn to leverage their compound libraries for the benefit of patients across many different therapeutic indications."
Dr Andrew (Andy) Haigh, President and CEO of Adapsyn Bioscience, said: "This exciting collaboration will allow Adapsyn to benefit from the breadth and depth of Evotec’s natural product development expertise and provides a mechanism to evaluate our chemistry against an expanded range of targets and screening modalities. We are thrilled to partner with Evotec and we look forward to a productive relationship that builds on our collective strengths."